Drug reference

magnesium

L-type Ca2+ channel blocker, RyR2 inhibitor · Antiarrhythmic

L-type Ca2+ channel blocker, RyR2 inhibitorAntiarrhythmicATC A12CC02

CDSCO approvedATC A12CC02

EXCRETION

—

not curated

INTERACTIONS

6 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 9 →

BictegravirSevereDatabaseDDInter
DolutegravirSevereDatabaseDDInter
ErdafitinibSevereDatabaseDDInter
PatiromerSevereDatabaseDDInter

Mechanism

Magnesium is effective by blocking L-type Ca2+ currents responsible for the triggered upstroke arising from EADs. It is also an inhibitor of RyR2 Ca2+ release channels.

Indications

Preventing recurrent episodes of torsades de pointes (even with normal serum Mg2+)Arrhythmias related to digitalis intoxication

Dosing

Adult: 1–2 g MgSO4 (IV)

Pharmacokinetics

Protein binding

Not specified

Drug interactions

Bictegravir

Severe

Database

Clinical effect not specified

Source: DDInter

Dolutegravir

Severe

Database

Clinical effect not specified

Source: DDInter

Erdafitinib

Severe

Database

Clinical effect not specified

Source: DDInter

Patiromer

Severe

Database

Clinical effect not specified

Source: DDInter

Selpercatinib

Severe

Database

Clinical effect not specified

Source: DDInter

Tolevamer

Severe

Database

Clinical effect not specified

Source: DDInter

Tetracyclines

Moderate

Textbook

Poor absorption of tetracycline.

Avoid concurrent ingestion. Dairy products, antacids, aluminum hydroxide gels; calcium, magnesium, iron, or zinc salts; bismuth subsalicylate; and dietary iron and zinc supplements can interfere with absorption of tetracyclines. Omadacycline specifically requires administration on an empty stomach, at least 4 hours after and 2 hours before food consumption. Food, including dairy products, does not interfere with absorption of doxycycline and minocycline but significantly impairs the absorption of omadacycline.

Source: G&G 14e · p1181

Elvitegravir

Moderate

Database

Reduced bioavailability of elvitegravir.

Subject to similar restrictions as raltegravir (take 6h before or 2h after).

Source: DDInter

Gabapentin

Moderate

Database

Antacids reduce gabapentin bioavailability by ~20% through chelation and/or reduced gastric residence time.

Separate administration by at least 2 hours. Give gabapentin at least 2 hours after antacid dose.